Sigenergy's 20 MWh Modular C&I Solution Defines the Next Generation of Energy Storage
BURGAS, Bulgaria, June 3, 2025 /CNW/ -- Sigenergy brought together nearly 300 global energy professionals in Burgas to explore the future of commercial and industrial (C&I) energy storage. A key highlight of the event was a visit to a landmark 20 MWh project in Malko Tarnovo, powered by Sigenergy's modular C&I battery energy storage system (BESS). The project highlights the scalability and real-world impact of next-generation storage technology.
In partnership with Trakia MT Ltd., a leading Bulgarian solar company, the system is installed on a solar farm and features 90 Sigenergy C&I hybrid inverters combined with the SigenStack modular storage solution.
Tony Xu, Founder and CEO of Sigenergy, commented: "Sigenergy's mission is to accelerate the global transition to clean energy with innovative and scalable storage solutions. This project exemplifies how advanced battery systems can drive business growth and decarbonization across industries."
Modularity Transforming C&I Energy Storage
SigenStack introduces a truly modular approach to C&I energy storage—replacing bulky containerized systems with stackable 12 kWh battery packs. With plug-and-play connectors and tool-free installation, the system eliminates complex wiring, the need for cranes, and heavy machinery.
Thanks to this design, the entire 20 MWh system was installed in just 10 days and fully commissioned within 2 days. Galina Peycheva-Miteva, Owner of Trakia MT Ltd., noted: "The installation was incredibly smooth—more like assembling building blocks than deploying industrial infrastructure. This modular design is a game-changer for the C&I energy storage sector."
Safety Engineered at the Pack Level
Sigenergy's C&I BESS solutions set new benchmarks for system safety. At the heart of this innovation is the SigenStack system, engineered with safety at every level. Each 12 kWh battery pack features six layers of protection: temperature sensors, internal fire suppression units, aerogel insulation, decompression valves, high-temperature-resistant insulation pads, and smoke detectors. This configuration enables early detection of thermal runaway at the pack level and initiates a rapid, localized response within seconds.
In contrast, conventional cabinet-style systems typically lack compartmentalization and may take over a minute to react, increasing the risk of fire propagation. By isolating incidents at the module level, SigenStack significantly enhances system reliability and operational safety.
Its advanced inverter platform includes ultra-fast 500 ms anti-backflow protection and long-range arc fault circuit interrupter (AFCI) technology capable of detecting faults up to 500 meters.
To further validate its safety performance, Sigenergy partnered with global assurance provider Intertek to publish a C&I Safety White Paper. The results confirm full compliance with UL 9540A and IEC 62619, structural stability under extreme testing, and sustained operational efficiency above 95%.
Resilience Made for Zero Maintenance
Built on robust safety and modular design, Sigenergy's C&I BESS supports 24/7 autonomous operation. With an IP66 rating for dust and water resistance, it delivers reliable performance across diverse environmental conditions. Conventional cabinet-style systems, however, often contain more vulnerable components and demand monthly inspections, half-year part replacements, and comprehensive annual maintenance.
Real-time monitoring via a cloud-based platform provides full visibility into system status, energy throughput, and alarms, significantly reducing the need for on-site inspections. Maintenance is also streamlined: faulty battery packs can be replaced individually within two hours, without full system diagnostics or on-site technician intervention. This reduces downtime, simplifies spare parts logistics, and minimizes operational costs.
The successful delivery of this project demonstrates Sigenergy's excellence in installation speed, safety, operational reliability, and smart management. Looking ahead, Sigenergy is committed to expanding its global footprint, driving the adoption of safer, more efficient, and sustainable energy solutions worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/sigenergys-20-mwh-modular-ci-solution-defines-the-next-generation-of-energy-storage-302472199.html
SOURCE Sigenergy Technology Co., Ltd.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/03/c0258.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Canadians to benefit from enhanced free and low-cost bank accounts later this year
OTTAWA, ON, June 5, 2025 /CNW/ - Thirteen federally regulated financial institutions, including Canada's 6 largest banks, have signed on to a modernized Commitment on Low-Cost and No-Cost Accounts. By December 1, 2025, Canadians will benefit from modernized no-cost and low-cost accounts costing no more than $4 per month. Going forward, under these accounts, Canadians will have access to 50% more debit transactions per month, including widely used transaction types such as electronic fund transfers (e.g. Interac e-Transfers®). More groups will also be eligible for an account costing $0 per month, including newcomers to Canada in their first year, plus at least one of the following groups, to be selected by each signatory: Indigenous peoples Canadians receiving social assistance payments from select provincial or territorial programs individuals with a valid Disability Tax Credit Certificate and/or their supporting family member Financial institutions that have signed on to the Commitment will prominently display information about the availability of low-cost and no-cost accounts in-branch and online, and will train staff about these account options. Canadians can currently get low-cost and no-cost accounts from nine signatories under the original 2014 Low-cost and No-cost Accounts Commitment. The Financial Consumer Agency of Canda (FCAC) will monitor the implementation of the modernized Commitment by signatories and will supervise their compliance with all its obligations. In Budget 2024, the government announced its intention to secure a new commitment from financial institutions for enhanced free and affordable bank accounts, recognizing that Canadians' banking needs have changed with the increase in online banking. Quotes "Every Canadian deserves access to affordable, modern banking. That's why we worked with the FCAC to strengthen the commitment by financial institutions on free and low-cost bank accounts – more transactions, fewer fees and better access. This is a clear step toward fairer, lower-cost banking for all." The Honourable François-Philippe Champagne, Minister of Finance and National Revenue "The Financial Consumer Agency of Canada puts the rights and interests of Canadians first. I am pleased that more Canadians will benefit from modern and affordable bank account options that include more transactions, offered by more financial institutions, to more groups. Having 13 signatories commit to offering modernized low-cost and no-cost accounts is good news for financial consumers. I encourage other financial institutions to join the Commitment and extend these benefits to even more Canadians." Shereen Benzvy Miller, Commissioner, Financial Consumer Agency of Canada Quick facts The Financial Consumer Agency of Canada's (FCAC) mandate is to supervise the compliance of federally regulated financial entities, including banks, with their legislative obligations, codes of conduct and public commitments and to strengthen the financial literacy of Canadians. The following federally regulated financial institutions have signed on to the modernized Commitment so far: Alterna Bank BMO CIBC Hana Bank Canada ICICI Bank Industrial Commercial Bank of China Innovation Federal Credit Union Laurentian Bank National Bank Royal Bank of Canada Scotiabank Tangerine Bank TD Bank FCAC supported the development of the modernized Commitment based on research and consultations with Canadians, stakeholders and industry. This work underlined the need to update the Commitment to reflect consumers' evolving banking needs and to support financially vulnerable Canadians, while recognizing the importance of innovation and competition in the financial marketplace. FCAC encourages Canadians to shop around for banking products and services that meet their needs. FCAC provides useful and unbiased resources to help consumers make informed financial decisions, including a Bank Account Comparison Tool and information about: low-cost and no-cost accounts choosing financial products and services transferring products or services to another financial institution choosing a financial institution Associated links The modernized Commitment on Low-Cost and No-Cost Accounts 2014 Commitment on low-cost and no-cost accounts Search for related information by keyword: Finance | Personal finance | Financial Consumer Agency of Canada | Canada | Money and finances | general public | news releases SOURCE Financial Consumer Agency of Canada View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors on June 11, 2025 beginning at 9:00 a.m. ET in New York City. Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer, John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, BJ Jones, Chief Commercial Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President. A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL CVOT in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP:
Bloomberg
an hour ago
- Bloomberg
Canada Trade Deficit Hits Record as US Tariffs Crush Exports
By Updated on Save Canadian exports plunged by the most in nearly 17 years outside of the pandemic, widening the country's merchandise trade deficit to the largest on record. With demand from the US cratering due to the Trump administration's tariffs, Canada's trade deficit reached C$7.1 billion ($5.2 billion) in April, from C$2.3 billion, according to Statistics Canada data Thursday. The deficit far exceeded even the most pessimistic projection in a Bloomberg survey of economists.
